Your session is about to expire
← Back to Search
Dietary Supplement
Choline for Alzheimer's Disease
Phase 1
Recruiting
Led By Paul E Schulz, MD
Research Sponsored by Paul E Schulz
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights
No Placebo-Only Group
Summary
This trial tests if choline bitartrate, a dietary supplement, can help people at risk of Alzheimer's Disease. The supplement aims to improve how brain cells handle fats, potentially keeping them healthy and functioning properly.
Who is the study for?
This trial is for adults aged 55-80 who are at risk of Alzheimer's but not yet showing symptoms. They must have a certain gene variant (ApoE4), normal thinking skills, and good general health based on medical exams. Women should be post-menopausal or unable to bear children. People with other serious diseases, high choline diets, or unwillingness to undergo certain tests can't join.
What is being tested?
The study is examining the safety and potential effects of choline—a dietary supplement—on individuals who are at increased risk for Alzheimer's Disease but do not yet show symptoms. The goal is to see if choline influences the progression towards Alzheimer's.
What are the potential side effects?
As a dietary supplement, choline is generally considered safe; however, possible side effects in the context of this trial may include digestive issues like nausea or diarrhea, fishy body odor when taken in large amounts, and potentially low blood pressure.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 9 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Changes in phosphatidylcholine (PC) in the CSF following choline supplementation
Changes in the fatty acid desaturation index (FADI) in the CSF following choline supplementation
Secondary study objectives
Changes in amyloid-β 42/40 ratio CSF following choline supplementation
Changes in choline in blood following choline supplementation
Changes in neurofilament light chain (Nf-L) in CSF following choline supplementation
+5 moreOther study objectives
Change in Functional Activities Questionnaire (FAQ) scores following choline supplementation
Change in Mini-Mental Status Examination (MMSE) following choline supplementation
Change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores following choline supplementation
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CholineExperimental Treatment1 Intervention
2.2 g of choline, given as choline bitartrate, for a total of 180 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Choline
2021
Completed Phase 4
~630
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Alzheimer's Disease, such as cholinesterase inhibitors (donepezil, rivastigmine, and galantamine), work by inhibiting the enzyme that breaks down acetylcholine, thereby increasing its levels in the brain. This enhancement of cholinergic transmission helps improve cognitive functions like memory and learning, which are typically impaired in Alzheimer's patients.
Similarly, choline, an investigational treatment, supports acetylcholine synthesis, potentially offering another avenue to boost cognitive function. These treatments are crucial as they aim to alleviate the symptoms of Alzheimer's by addressing the neurotransmitter deficits that contribute to cognitive decline.
Find a Location
Who is running the clinical trial?
Paul E SchulzLead Sponsor
M.D. Anderson Cancer CenterOTHER
3,074 Previous Clinical Trials
1,803,531 Total Patients Enrolled
Massachusetts Institute of TechnologyOTHER
101 Previous Clinical Trials
12,822,011 Total Patients Enrolled
Balchem CorporationUNKNOWN
2 Previous Clinical Trials
1,540 Total Patients Enrolled
Paul E Schulz, MDPrincipal InvestigatorThe University of Texas Health Science Center at Houston (UTHealth)
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I cannot or do not want to have lumbar punctures.I have had cancer in any part of my body in the last 5 years.My health condition is stable and does not pose a risk to my safety in the study.I do not have any conditions like TBI, Parkinson's, or MS affecting my thinking.I am between 55 and 80 years old.I have at least one ApoE4 gene.I am post-menopausal or cannot become pregnant.
Research Study Groups:
This trial has the following groups:- Group 1: Choline
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.